In addition, compared with the low-risk group, focal amplification peaks were observed for well-characterized cancer-related genes HAS2 (8q24.13) and PDGFRA (4q12), which might be the reason for the poor outcomes in the high-risk group. This evidence concerns the gene HAS2 and cancer.